Cysteine cathepsins, a class of proteinaceous enzymes, regulate a wide variety of metabolic processes in human including protein breakdown and turnover and immune functions. Eleven cysteine cathepsins have been identified so far and a wide array of studies related to identifying their specific functions, regulation and distribution patterns in tissues have been conducted.
Proteases or proteolytic enzymes are a group of proteinaceous enzymes that are involved in the process of catalysing the hydrolysis process of amide bonds in biomolecules. However, unlike the reversible changes such as phosphorylation and allosteric site changes that proteins undergo, proteolysis in general is considered to be an irreversible change 1 . Cysteine proteases are one such group of proteolytic enzymes that involves in metabolism including protein degradation and turnover, bone remodelling and pre-hormone processing 2 . Apart from the structural analysis, a variety of functional analysis of these proteases have revealed, that in addition to their intracellular role in the process of recycling of proteins, they are also involved in other most usually occurring processes such as antigen presentation, bone remodelling, and prohormone activation 3 . Most remarkably, cysteine proteases are involved and are suggested to involve in a variety of disease processes such as pulmonary emphysema, osteoporosis, alzheimer's disease, rheumatoid arthritis, and also in cancer invasion and metastasis 4 .
These proteolytic enzymes can be sub dived into more than 20 classes of different families, of which the members; papain, Calpains, Streptopains, Clostripains, Viral Cysteine Proteases and Caspases are some prominent ones 5 . However, the largest noted family is the Papain family. This family as a whole consists of a variety of cysteine proteases that are derived from both eukaryotes and prokaryotes. As far as human cysteine proteases belonging to the papain family are concerned, it has been found to include a variety of Cathepsins 6 . Studies done on the structural analysis of cysteine cathepsins have proven that all of them contain a series of conserved features or rather domains which include an essential cysteine residue within each one of its active sites that determine its specific function. It has also been studied that cysteine proteases are synthesized as preproenzymes, which are processed to the corresponding proenzymes and oriented on to the lysosomes by the mannose 6-phosphate signal that is attached to them 7 . However, certain differences within these enzymes such as differences in distribution in their tissues and in certain other enzymatic properties such as exhibiting optimal activity in a slightly acidic pH and been mostly unstable at neutral pH that regulate systemic metabolism that collectively account for substrate specificities and pH stability are also noted 4 . In addition, it should also be noted that when cathepsins are found outside the lysosomes or found extracellularly they could rapidly irreversibly achieve an inactive status at neutral pH.
Cathepsin is derived from the Greek word "kathepsein" which means to digest, was proposed for the proteases that showed activity in a slightly acidic environment. Eleven human Cysteine Cathepsins have been found and studied which are Cathepsins B, C, F, H, K, L, O, S, V, X and W which was confirmed by a bioinformatic analysis of the sequence of the human genome (8) .
Lysosomal Cathepsins needs a reducing and a slightly acidic environment in order for them to show optimum function, such as found in the lysosomes, and hence become active 9 . Therefore, Cysteine Cathepsins were initially considered to be solely intracellular enzymes, responsible for non-specific and mass proteolysis in acidic environment of the endosomal or rather lysosomal compartment, where they degrade intracellular and extracellular proteins. However, this concern over these enzymes are rapidly changing and under intensive research (8) .
In human, Cathepsins such as B, H, L, C, X, F, O and V are highly expressed in all most all human tissues. The most basic expression profiles of these enzymes show that these enzymes are involved in normal, cellular protein degradation and turnover 10 . In contrast, Cathepsins K, W and S show up only in limited cells or tissues, rather show a tissue specific distribution nature, thus indicating more tissue specific functions as well. For instance, Cathepsin K is highly seen to express in osteoclasts and highly specific in function, which is to involve in bone tissue resorption 10 .
Similarly, Cathepsin W is predominantly expressed in CD8+ lymphocytes 11 . As far as the physiology of the cysteine cathepsins are concerned, they show optimum activity in slightly acidic pH and mostly unstable at neutral pH 12 . Except for Cathepsin S, when the other cathepsins are outside the lysosomes or the lysosomal compartments, or present extracellularly, they could relatively but yet rapidly undergo irreversible inactivation, given that the pH is neutral in nature 13 .
Main text
This review focuses on the molecular functional and structural characterization studies that have been done with regard to the in vitro expression of genes encoding for human cysteine proteases in bacterial expression systems. More emphasis is given to the expression of human cysteine cathepsins which is considered to be a sub class that belongs to cysteine proteases, in the Escherichia coli (E. coli) bacterial expression system as the host. The review also collects together and summarises the published expression conditions of different cathepsins in E. coli.
An expression study of Cathepsin O which involved the molecular cloning of genetic material from a breast cancer carcinoma and production of the active enzyme in E. coli, and expression analysis in human tissues done by Velasco and colleagues reflect where the Cathepsin O cDNA cloned from a human breast cancer carcinoma was expressed in E. coli. After optimum purification and refolding, the recombinant protein was able to degrade the synthetic peptide benzyloxycarbonyl-Phe-Arg-7-arnido-4-methylcoumarainnd-b-enzyloxycarbonyl-Arg-Arg-7amido-4-methylcouma, which is widely used as a substrate for the entire group of cysteine proteases enzymes 14 . In the meantime, it was also observed that proteolytic activity of the recombinant Cathepsin O so produced was completely terminated by trans-epoxysuccinylleucylamido-(4-guanidino) buta(nE"e) 14 an inhibitor of this subclass of proteolytic enzymes, further validating that the recombinant protein produced had the conserved domains that feature Cysteine Cathepsins in human. Moreover, in the work published, a 930 bp DNA fragment containing the complete coding sequence for human Cathepsin O was obtained through PCR amplification of the isolated full-length cDNA with the primers 5'-ATGGACTCCCGCGCCCCC-3' and 5'-CTGTCTCTTGATCTGCCCA-3'. Accordingly, a Polymerase Chain Reaction (PCR) was carried out for a total of 25 cycles with conditions which consisted of a 95 o C, 1 minute denaturation, 50 o C, 1 minute annealing and 72 o C, 1 minute extension phase. The PCR product was then phosphorylated with T4 polynucleotide kinase and ligated to the expression vector pET3c which was previously treated with NdeI and Nuclease S1. The resulting plasmid which was called pETH7, was transformed into E. coli strain BL21(DE3), and the transformed cells were grown in Luria Bertani (LB) media containing ampicillin with an incubation at 37 o C for nearly 16 hours and was screened out accordingly 2 . Further studies that were done in the form of enzyme activity assays confirmed that this recombinant cysteine protease produced was Cathepsin O 15 . This study suggested that the mass production and availability of recombinant Cathepsin O would be of highly useful to study the potential role in the pathological protein breakdown occurring in degradative and invasive processes associated with proteins. The study also suggested that, with the availability of recombinant Cathepsin O, it would be possible to investigate the correlation between alterations in expression of this enzyme and intracellular trafficking of Cathepsin O, would have with malignancy and the formation of cancers in human 16 . Furthermore, published literature showed studies expressing the Cathepsin F in E. coli. A cDNA encoding for Cathepsin F was obtained from a human prostate cDNA library which encoded for a polypeptide of 484 amino acids. In the study, recombinant Cathepsin F that was produced by E. coli as a fusion protein with glutathione S-transferase degraded the synthetic peptide benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin 14 , which is a substrate that is commonly used for functional characterization of cysteine proteases As far as the molecular cloning of this experimental study is concerned, a 647 bp DNA fragment containing the coding sequence for the mature human Cathepsin F was amplified by PCR amplification of the isolated full-length cDNA with the use of primers 5'-ATGGCCCCACCTGAATGGGACT-3' and 5'-TCAGTCCACCACCGCCGAG-3'. The PCR reaction was carried out for 20 cycles which consisted of the phases; denaturation at 95 °C for 30 seconds, annealing at 60°C for 30 seconds and an extension phase at 68°C for 1 minute. The PCR amplicons were then phosphorylated with T4 polynucleotide kinase followed by repairing with the Klenow fragment, and was ligated to the expression vector pGEX-3X which was previously treated with the restriction endonuclease SmaI and alkaline phosphatase. The plasmid that resulted, which was called pGEX-3X CTSF, was transformed into E. coli strain BL21(DE3) and the transformed cells were grown in LB media containing ampicillin at an incubation at 37°C for 16 hours 4 . Further enzymatic studies, chromosomal mapping and northern blot analysis confirmed that the recombinant protein so produced, absolutely was Cathepsin F. As a result of the chromosomal mapping an evolutionary study of the enzyme was also facilitated. The evolutionary study was conducted using phylogenetic analysis which validated the fact that Cathepsin F is more closely related to Cathepsin W in human 17 . An important outcome of this study was that recombinant Cathepsin F could be useful for searching putative genetic diseases and different forms of occurrence of cancers associated with the gene coding for Cathepsin F in human. From previous literature it was found that the levels of expression of Cathepsin F is very high compared in the human skeletal muscle and the testis in male 18 . Therefore, now with the availability of recombinant Cathepsin F, further studies could be conducted to find out the most effective protein substrate catabolism process that is been carried out by Cathepsin F in skeletal muscles 19 and any suggestive role of Cathepsin F in male fertility, avenues that are very rarely thought of compared to the typical reasons for the loss of male fertility.
Expression analysis of Cathepsin F has also revealed the presence of this enzyme in several human cancer cell lines, significantly high in HeLa cells 20 . As a result, the recombinant Cathepsin F could be used in further clinical trials that could facilitate the establishment of effective therapeutics against such cancers as per the necessity.
In another study which involved in characterizing the enzyme Cathepsin Z, a full-length cDNA encoding for this enzyme was cloned from a human brain cDNA library 21 . Nucleotide sequence analysis revealed that the isolated cDNA codes for a polypeptide of 303 amino acids; Cathepsin Z and this cDNA was expressed in E. coli as a fusion protein with glutathione S-transferase, and after optimum purification, the so produced recombinant protein was capable of degrading the synthetic peptide benzyloxycarbonyl-Phe-Arg-7-amido-4 methylcoumarin, which is effectively utilized as a substrate by cysteine proteases (14) . As far as the platform of work associated with molecular cloning in this study is concerned, firstly, an appropriate expression vector that is suitable for the production of recombinant cathepsin Z in E. coli, was produced by generating a 727 bp DNA fragment containing the coding sequence for the mature human cathepsin Z by PCR amplification of the isolated full-length cDNA with the use of the primers 5'-ATGCTGCCCAAGAGCTGGGAC-3' and 5'-CGATGGGGTCCCCAAATG-3'. The PCR reaction was carried out for 30 cycles which consisted of the phases; denaturation at 95°C for 30 seconds, annealing at 56°C for 30 seconds and extension at 72 °C for 1 minute. The PCR product was accordingly phosphorylated with T4 polynucleotide kinase, repaired with the Klenow fragment, and ligated to the expression vector pGEX-3X which was previously treated with the restriction endonuclease SmaI and alkaline phosphatase. The plasmid that resulted was called pGEX-3X
CathZ and was transformed into the E. coli strain BL21(DE3), and the transformed cells were grown in LB media containing ampicillin at an incubation in 37°C for about 16 hours. Enzyme activity assays and Northern blotting analysis confirmed that the recombinant enzyme produced this way was particularly Cathepsin Z 21 . An important outcome of this study was that, it was found out that on analysis of the propeptide of the recombinant protein that was produced, it did not contain any lysine residue, which is contradictory to the fact that lysine based structures that were found present in the pro region of the other different Cathepsins were propose to act as the recognition sites for the mannose phosphorylation that is required for intracellular targeting of cysteine cathepsins 22 . Based on this important fact, the pro region of Cathepsin Z is markedly different from the previously characterized members of this protein family and suggests that it could be even of a different sub family of enzymes. Having considered this important hypothesis, chromosomal location of the Cathepsin Z gene has revealed that it maps to chromosome 20 23 .
This position differs from those that have been previously studied and reported for the remaining cysteine proteinase genes of the papain family. The study therefore, strongly emphasized that further studies are required in order to characterize the enzyme and ground it in the most appropriate class of the enzyme that it would belong to. As per the evidence derived from the work it was also noted that Cathepsin Z is expressed on all normal tissues in the body, and therefore suggests that a putative general role of this enzyme is noted in intracellular protein turnover to take place in all cell types of the body. With the availability of the recombinant Cathepsin Z enzyme, the potential effect that Cathepsin Z has on malignant cancers on human and other different protein degradative processes occurring in normal and pathological health conditions could also be studied in to further depth.
In the identification of a novel type of Cathepsin from a human brain cDNA library which coded for a polypeptide of 334 amino acids a high percentage of identity was seen to be established with Cathepsin L when pairwise comparisons with the other types of cysteine proteases was done. The percentage identity was noted to be 78% 24 . As a result, this Cathepsin was called Cathepsin L2.
When the cDNA encoding the mature Cathepsin L2 was brought to express in E. coli, and after sufficient and optimum purification, the so produced recombinant protein was capable of degrading the synthetic peptide benzyloxycarbonyl-L-phenylalanyl-L-arginine-7-amido-4rnethylcoumarln, which is a common substrate used by cysteine proteases 25 . In addition, the proteolytic activity on the same substrate mentioned above was abolished by the compound transepoxysuccinyl-L leucylamido-(4-guanidino) butane which is a common inhibitor for cysteine proteases 25 . This further proved that the cDNA that was isolated in the first place encoded for as validating the fact that Cathepsin L2 is also produced by certain renal and ovarian cancers in human 26 . Therefore, Cathepsin L2 could be characterized as an emerging cancer causing proteolytic enzyme, better defined, a Cysteine Cathepsin that has the potential to induce and cause severe cancer in human 26 . Procathepsin E gene. To facilitate the process of molecular cloning of these genes into an expression vector, the two oligonucleotides which were 5'-GCGAGCATGCCATGGGATCCCTTCACAGGGTG-3' and 5'-CACCGGTCGACTTAGGGGACTGCTGGGGC-3' were designed in such a way, which included the NeoI and SalI restriction endonuclease sites respectively, so that primer binding to the correct sites could be specifically and tentatively achieved. Extraction and purification of the 1,100 bp fragment that resulted and authentication of the oligonucleotide sequence was done using the dideoxy sequencing method. The NeoI-SalI fragment on both sides of the coding sequence for Procathepsin E, was reported to be subcloned into the T7 expression vector, pET22b and relevant expression studies were done by introducing the so created recombinant plasmid in the E. coli strain BL21(DE3) pLysS 28 . As mentioned above, the study involved many optimization procedures of the molecular techniques and expression systems. This itself seems to be a very important and a ground breaking outcome of the study, so that the recombinant Procathepsin E that could now be produced in large quantities, could be used in further studies related to pathological, pathophysiological, oncological and metabolism based on various clinical scenarios and as per the requirement since this study was able to resolve two major concerns which was to produce the recombinant Procathepsin E and also to purify it to optimum levels in such a way that the authentic properties of the protein still remained. As per published literature, Cathepsin E is also reported to be expressed in activated microglia, dendritic cells, macrophages and lymphocytes and also evident to be localized in distinct cellular compartments including the plasma membrane, endoplasmic reticulum and the golgi complex 29 . Studies also showed that Cathepsin E is also involved in the major histocompatibility complex class 2 mediated antigen presentation 3031 .
Therefore this suggests that the availability of recombinant Cathepsin E paves the pathway for better understanding of various aspects of physiology in human that could eventually lead towards the development of novel therapeutic agents that could promote human health, by combating various abnormal disease conditions that could arise as a result of deficiencies, mutations or any other abnormal presentation and activity of Cathepsin E.
Human Procathepsin S was reported to be produced in the form of inclusion bodies in E. coli using an inducible T7-based expression system. DNA encoding Procathepsin S was amplified from a human ileum cDNA library using PCR amplification protocols. The primers used for this amplification process were 5'-GGAATTCATATGGCACAGTTGCATAAAG-3' and 5'-CTCGGATCCGATCCTCTAGATTTCTGG-3' which were designed based on the cDNA sequence obtained 32 . In order to facilitate the process of cloning the PCR amplicons, with the restriction endonuclease sites EcoRI and NdeI were incorporated into the sense primer while the host cells, and those that contained Cathepsin B inserts were screened and transformed into other host strains for immuno-screening to verify that the protein produced was Cathepsin B. This was followed by IPTG induction and bacterial clones producing the immune reactive Cathepsin B were detected as dark spots on nitrocellulose filters as results of this study. Further characterization studies have been done on the bacterial gene products by subjecting them to protein blotting. Once they were made to undergo IPTG induction, one prominent protein band at approximately 33kDa was observed and moreover this band was absent in the lysate containing the opposite orientation plasmid and in addition, most importantly it was noted that the band obtained was also immune reactive to the human Cathepsin B antiserum. Thus, it was concluded on a strong scientific ground that the 33kDa Cathepsin B was produced by the pET3 expression vector system. In addition, the same study was also able to conclude that the expression of the enzyme Cathepsin B was stable in the host cells E. coli BL21(DE3) pLysS but not in the host cells E. coli BL21(DE3). This was reported to be justified upon the fact that the host cells E. coli BL21(DE3) pLysS has an additional plasmid coding for the T7 lysozyme gene that improves the expression features of the T7 gene expression system 36 . However, it should be noted that under the molecular protocol and the extent of optimizations in this study, unlike the normal Cathepsin B which is glycosylated 37 , expressed this way, the recombinant, Cathepsin B was not glycosylated. The study also suggested that the bacterially derived Cathepsin B could be used as a substrate as well for further studies on Cathepsin B processing enzymes.
In addition, a study focused on the preparation of catalytically active human Cathepsin B from its precursor, in order to express it in an expression system of E. coli in the form of inclusion bodies, has also been able to show remarkable results 38 . Accordingly, a cDNA clone that encodes the particular human Procathepsin B was expressed in E. coli using a T7 expression system which resulted in the formation of the recombinant protein in the form of insoluble cytoplasmic protein aggregates which are more or less known to be inclusion bodies 38 could occur since the refolding is carried out at alkaline pH, 40 which does not favour its conversion into the mature form which itself is an effective methodology that have been proposed to be carried out in the case of mass production requirements of Cathepsin B. Furthermore, Cathepsin B has been found to involve in the progression of cancer in human in aspects of capase dependent apoptosis and in the processes of facilitating tumour neovascularization and metastasis (Mijanovic, 2019) . Moreover, Cathepsin B was also found to be involved in cancer metastasis by making alterations in the extracellular matrix remodeling and facilitating invasion in different tissues of the body 42 . Such considerations provoke the fact that research related to investigating the most specific inhibitor for Cathepsin B needs to be encouraged and such studies could be facilitated very easily when recombinant production of Cathepsin B is made available.
In another molecular expression study, a cDNA clone encoding human cysteine protease Cathepsin L was expressed at satisfying levels in an E. coli expression system 43 . However, the recombinant protein produced was insoluble and had to be solubilized using chemical methods which involved solubilizing the protein produced in urea and facilitating to be refolded at an alkaline pH. However, in terms of stability, the recombinant enzyme showed very less stability compared to the original human enzyme or rather the authentic form of the enzyme. Structural and functional characterization studies of Cathepsin L were performed by means of inducing mutations specifically, in either the propeptide portion or the carboxyl terminal light chain of the protein and the genes with these mutations induced were expressed in the E. coli expression system and further investigations were done within the same study were done to assess a variety of enzymatic features such as solubility and purity that it exhibited. In the aspect of molecular characterization, recombinant human Cathepsin L was made to produce in E. coli using a gene expression system based on inducible T7 RNA polymerase synthesis of recombinant fusion proteins, which was followed up by the IPTG induction of a T7 RNA polymerase gene under lacUV5 control inserted in the bacterial chromosome. The induced T7 polymerase transcribed the genes cloned downstream from a polymerase-specific T7 promoter in a particular expression vector. Even though the human Cathepsin L cDNA constructions containing the entire protein-coding sequence were not expressed at appreciable levels by this system, several constructions lacking the signal peptidecoding sequence were noted to express efficiently which itself was a noteworthy outcome of the study that was conducted 43 . The study suggests that this ability to produce large amounts of enzymatically active Cathepsin L in E. coli will make it possible to produce large amounts of enzyme for structural studies and other studies with pathophysiological implications 44 , while making it possible to perform detailed analysis on additional mutant forms and gross studies that could relate to the metabolism and other properties of this enzyme which is known to be an acid protease 45 . A recent study was also able to reveal that Cathepsin L has a regulatory effect on neuroretinal homeostasis by regulating a variety of inflammatory effects that are related with age related macular degradation in human 46 . Such homeostatic processes that function in the body could be better understood with the availability of recombinant Cathepsin L and accordingly, efficient inducers or inhibitors that are capable of determining the rate of such enzyme catalysed biochemical processes in the body could be controlled. In addition, a study which evaluated the effect of cysteine cathepsins on the development of the brain at various stages of life showed that the human brain utilized well defined and highly balanced patterns of cathepsin gene expression throughout the different stages of the development of the brain during the different stages of life 47 . This study also suggested that this fact of utilization of cysteine cathepsins by the could be considered the base for other investigations to understand how cysteine cathepsins are dysregulated in lysosomal related brain abnormalities that affect the different age categories of human; from infants to adults. Accordingly, this establishes the fact that the availability of the recombinant enzymes of cysteine cathepsins could bring about a multitude of benefits in research that involves the study of metabolic processes in the human body, including their physiology in total, the related pathophysiology and other biochemical process in the body that regulate growth, development and wellbeing.
Conclusion
Cysteine Cathepsins play a vital role in the overall metabolism of human that ensure survival of them. Therefore, it is of great importance to investigate whether the genes encoding for these enzymes could be expressed in microbial expression systems, especially bacterial expression systems, to identify the production of these enzymes within such systems in order to facilitate the production of therapeutics that contain the enzyme as an active component within. As per the published literature that is available in global databases such as the NCBI and PUBMED and Google scholar it is also understood that the expression of the genes responsible for the production of the enzymes Cathepsins K, C, H, X and W, were not seen in bacterial expression systems so far.
However, expression of these enzymes in E. coli expression systems could give rise to the manufacture of therapeutics containing these enzymes that could be used to treat or control metabolic abnormalities or any related disease, especially a wide variety of cancers ranging from breast cancers, prostate cancers to ovarian cancers. Accordingly, it could also lead towards understanding their pathophysiology, the effect of human Cathepsins on the variety of carcinomas, their regulation, control and behaviour that could shower a multitude of benefits on a global outlook since cancer has been one of the major non communicable deadly diseases throughout the world today. It could also fast track oncological research to study the correlation that exist between cancers and cathepsin expression in tissues. Therefore, it is evident that the expression of cysteine cathepsins in bacterial expression systems could also open up a pool of other potential research avenues. The authors therefore suggest the other cysteine cathepsins too need to be characterized structurally and functionally on a molecular approach or rather a platform, so that the mass production of these enzymes could create impact in many fields including in the drug and pharmaceutical industry. The authors also suggest investigating better substrates that are uniquely
